NCT07898124 — Metaclipse Therapeutics cancer vaccine trial
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma
Registry record
| Registry ID | NCT07898124 ↗ |
|---|---|
| Lead sponsor | Metaclipse Therapeutics Corporation |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local, Recurrent Head and Neck Squamous Cell Carcinoma |
| Enrollment | 30 participants (target) |
| Start date | 2026-10-01 |
| Primary completion | 2030-12-31 (est.) |
| Last registry update | 27 Oct 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07898124), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07898124?
NCT07898124 (TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma) is registered on ClinicalTrials.gov as Phase 1, sponsored by Metaclipse Therapeutics Corporation.
Is NCT07898124 recruiting?
As of the 2026-10-27 registry update, NCT07898124 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07898124?
The lead sponsor is Metaclipse Therapeutics Corporation.
What condition does NCT07898124 study?
The registered conditions are Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local, Recurrent Head and Neck Squamous Cell Carcinoma. Primary completion is listed as 2030-12-31 (estimated).
Are results available for NCT07898124?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07898124.
Back to the full neoantigen vaccine trial tracker — 106 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.